Welcome to our dedicated page for Legend Biotech Corporation American news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech Corporation American stock.
Legend Biotech Corporation reports news on cell therapy development and commercialization, centered on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for relapsed or refractory multiple myeloma developed and marketed with Johnson & Johnson. Company updates commonly cover CARVYKTI sales trends, treatment-site expansion, manufacturing capacity, clinical and real-world data from the CARTITUDE program, and label or evidence developments tied to multiple myeloma care.
Legend Biotech news also follows its broader cell therapy pipeline, including allogeneic and in vivo CAR-T programs such as LUCAR-G39D in B-cell non-Hodgkin lymphoma. Recurring announcements include quarterly financial results, scientific-conference presentations, research and manufacturing priorities, advisory input, and corporate governance updates.
Legend Biotech (LEGN) will present updated long-term and real-world data from its CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) clinical program at the 23rd International Myeloma Society Annual Meeting in Glasgow, Scotland, on September 23-26, 2026.
Key presentations include updated long-term follow-up from the Phase 2 CARTITUDE-2 Cohort A trial in lenalidomide-refractory relapsed or refractory multiple myeloma (RRMM) after 1–3 prior lines of therapy, real-world outcome data from the eMMpower-CART study, and first results from a noninterventional, prospective post-authorization safety study in RRMM. Legend Biotech states that these data further characterize CARVYKTI use across earlier-line and real-world settings.
The release also reiterates extensive safety information for CARVYKTI, including boxed warnings for cytokine release syndrome, neurologic toxicities (including ICANS and parkinsonism), HLH/MAS, prolonged or recurrent cytopenias, immune effector cell-associated enterocolitis, and secondary hematological malignancies, with quantified incidence and timing data from CARTITUDE-1 and -4.
Legend Biotech (NASDAQ: LEGN) announced that interim CEO Alan Bash will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 2:35 p.m. ET. A live webcast and replay will be accessible through the company’s Investor Relations website.
Legend Biotech (NASDAQ: LEGN) reported strong second quarter 2026 results, driven by CARVYKTI® growth and expanding cell therapy programs. CARVYKTI® net trade sales rose 50% year-over-year to approximately $657 million, with availability extended to 348 global sites across 19 markets, including a launch in Ireland.
Total revenue increased to $387.5 million from $255.1 million a year earlier, producing operating income of $57.7 million versus a prior-year loss and net income of $33.2 million versus a $125.4 million loss. Legend Biotech highlighted positive first-in-human data for in vivo CAR-T candidate LB2501 and DLL3-targeted CAR-T LB2102. The company ended June 30, 2026 with about $965 million in cash, cash equivalents and time deposits, supported by net proceeds of roughly $212 million from a 7.7 million ADS offering, and believes this provides runway beyond 2026 as it targets company-wide profit based on adjusted net income.
Legend Biotech (NASDAQ: LEGN) will host an investor conference call and live audio webcast at 8:00 a.m. ET on Tuesday, August 11, 2026, to review its second quarter 2026 financial results. Senior management will provide an overview of the company’s quarterly financial performance.
According to Legend Biotech, investors and interested parties can access the live webcast via a provided weblink, with a replay and the earnings press release available about two hours after the call in the Investor Relations section of its website under Events and Presentations.
Legend Biotech (NASDAQ: LEGN) announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective July 24, 2026. Dr. Huang will remain as an advisor through August 2026 to support a smooth transition.
The Board has appointed Alan Bash, currently President of the CARVYKTI Business Unit, as Interim Chief Executive Officer and has begun a comprehensive search for a permanent successor. Board Chairman Frank Zhang emphasized continuity, execution, and focus on growth, while Dr. Huang expressed confidence in the company’s strategy, pipeline and long-term opportunities.
According to Legend Biotech, Bash’s immediate priorities as Interim CEO include ensuring business continuity, maintaining execution, and advancing commercial, clinical and operational priorities centered on CARVYKTI and the company’s broader cell therapy pipeline.
Legend Biotech (NASDAQ: LEGN) priced an underwritten public offering of 7,700,000 ADSs, each representing two ordinary shares, at $29.35 per ADS. The company expects gross proceeds of about $226 million, excluding any exercise of the underwriters’ 30-day option for up to 1,155,000 additional ADSs.
The offering is expected to close on June 23, 2026, subject to customary conditions.
Legend Biotech (NASDAQ: LEGN) has commenced an underwritten public offering of $225 million of American Depositary Shares (ADSs), each ADS representing two ordinary shares. All ADSs will be sold by the company, with a planned 30-day 15% underwriter option.
The offering, made from an effective SEC shelf registration, is subject to market conditions, so timing, completion, and final size remain uncertain.
Legend Biotech (NASDAQ: LEGN) reported first clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T for relapsed/refractory B-cell non-Hodgkin lymphoma.
In a 12-patient Phase 1 study, dose level 2 achieved 100% ORR and 83.3% CR with ongoing responses and a favorable safety profile without lymphodepletion.
Legend Biotech (NASDAQ: LEGN) reported first clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T, in relapsed/refractory B-cell non-Hodgkin lymphoma. In a Phase 1 trial, a single infusion at the higher dose achieved 100% ORR and 83.3% CR without lymphodepletion.
LB2501 showed dose-dependent in vivo CAR-T expansion, Grade 1–2 IRR/CRS only, no DLTs, SAEs, ICANS, or deaths, plus rapid vector clearance and polyclonal vector integration.
Legend Biotech (NASDAQ: LEGN) will present initial Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, at EHA 2026 in R/R B-cell NHL.
At dose level 2, ORR was 100% (6/6) with CR rate 83.3% (5/6), all ongoing at cutoff, with dose-dependent in vivo CAR-T expansion and no DLTs, SAEs, deaths or ICANS reported. CRS and infusion reactions were ≤ Grade 2.